insights_auto
Kāpēc uzņēmuma NVO akciju cena ir pieaugusi 2,40%?
Atklājiet vairāk iespējuchevron_right
NVO:NYSE
Novo Nordisk A/S
41,63 $
arrow_upward
+2,40%(+0,98) 1 d.
41,44 $
arrow_downward
-0,46% (-0,19)bedtimePēctirdzniecības
Slēgts: 13. nov., 16:00:04 GMT-5 · USD
search
Visi simboli
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: NVO…
Atvērt
40,97 $
Augsta
41,80 $
Zema
40,64 $
Tirgus kapitalizācija
142,04 mljrd.
Vid. apjoms
11,57 milj.
Apjoms
11,71 milj.
Dividende
4,32%
Ceturkšņa dividendes
0,45 $
Datums, kad tiek pārtraukta dividenžu izmaksa
2026. gada 14. aug.
Cenas/peļņas attiecība
11,05
Augstākā 52 ned.
64,16 $
Zemākā 52 ned.
35,12 $
Peļņa uz vienu akciju
3,77 $
Beta
0,69
Apgrozībā esošās akcijas
3,39 mljrd.
Darbinieku skaits
67 tūkst.
Atvērt
40,97 $
Augsta
41,80 $
Zema
40,64 $
Tirgus kapitalizācija
142,04 mljrd.
Vid. apjoms
11,57 milj.
Apjoms
11,71 milj.
Dividende
4,32%
Ceturkšņa dividendes
0,45 $
Datums, kad tiek pārtraukta dividenžu izmaksa
2026. gada 14. aug.
Cenas/peļņas attiecība
11,05
Augstākā 52 ned.
64,16 $
Zemākā 52 ned.
35,12 $
Peļņa uz vienu akciju
3,77 $
Beta
0,69
Apgrozībā esošās akcijas
3,39 mljrd.
Darbinieku skaits
67 tūkst.
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
The Motley Fool
·
pirms 1 stundas
Novo Nordisk vs. Pfizer: Does a Weight Loss or Cancer Focused Pharma Stock Make a Better Buy for 2027?
Benzinga
·
pirms 1 dienas
Novo Nordisk Scores EU Win For Hemophilia Drug, Advances Sickle Cell Treatment Toward Approval
Traders Union
·
pirms 1 dienas
Novo Nordisk stock rises over 2% as company pledges $200 million to World Diabetes Foundation and lifts guidance
Zacks
·
pirms 1 dienas
Pfizer Stock Down 6% Post Q3 Earnings: Time to Buy, Hold or Exit?
Profils
Novo Nordisk A/S, doing business as Novo, is a Danish multinational pharmaceutical company. Novo manufactures and markets pharmaceutical products and services, primarily obesity and diabetes medications and devices. The corporation was created in 1989, through a merger of two Danish pharmaceutical companies, which date back to the 1920s.
Novo employs approximately 69,500 people in 80 countries, and markets its products in approximately 170 countries. Novo is controlled by majority shareholder Novo Holdings which holds 28% of its shares and a majority of its voting shares.
Novo is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights. It is a leader in the FTSE4Good Index, and the only European company in the top ten.
Novo is the largest pharmaceutical company in Denmark. In 2023, Novo's market capitalization exceeded the GDP of Denmark, and it became the highest valued company in Europe. Wikipedia
Par “Novo Nordisk A/S”
ĢenerāldirektorsMike Doustdar
Darbinieki66,7 tūkst.
Dibināšanas datums1923
Galvenais birojsBagsværd, Galvaspilsētas reģions, Dānija
SektorsHealth Care
Nozare-
Tīmekļa vietnenovonordisk.com